ESC Universal Heart Failure Algorithm (2023 Guideline Integration Tool)
Patient assessment
Complete the clinical and laboratory fields to generate a structured review.
How to interpret this tool
This tool groups LVEF as HFrEF (≤40%), HFmrEF (41–49%), or HFpEF (≥50%) and provides a structured checklist for therapy and referral discussions. HFmrEF/HFpEF diagnosis requires symptoms or signs and supporting clinical evidence; LVEF alone is not diagnostic.
The 2023 ESC focused update recommends dapagliflozin or empagliflozin for symptomatic HFmrEF and HFpEF to reduce HF hospitalisation or cardiovascular death. HFrEF therapy should generally include the four foundational medication classes when appropriate, with patient-specific sequencing and monitoring.
Device eligibility is not determined by LVEF, QRS, and LBBB alone. Confirm symptoms despite optimal therapy, rhythm, aetiology, expected survival, patient preferences, and the complete guideline criteria before referral or implantation decisions.
References and evidence base
ESC 2023 Focused Update
McDonagh TA, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023;44(37):3627–3639.
Official article · doi:10.1093/eurheartj/ehad195
ESC 2021 Heart Failure Guideline
McDonagh TA, et al. European Heart Journal. 2021;42(36):3599–3726.
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.